Show simple item record

dc.contributor.authorGilbar, Peter
dc.contributor.authorMcPherson, Ian
dc.contributor.authorSorour, Natacha
dc.contributor.authorSanmugarajah, Jasotha
dc.description.abstractAim: To determine the incidence of febrile neutropenia (FN) following adjuvant chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) for early-stage breast cancer and the grade of neutropenia after cycle one. Methods: A retrospective multicenter audit of patients with early-stage breast cancer treated with TCH, was conducted at four Australian hospitals between October 2009 and September 2013. Results: Of 79 patients analyzed, data from 78 women were evaluated for FN incidence and data from 64 women were evaluated for grade of neutropenia. After cycle one of TCH, 26 patients developed FN (33.3%). Following all cycles, 32 patients developed FN (41.0%). There was no statistical difference in the incidence of FN between hospitals or between age groups (above or below 65 years). After cycle one, ten patients developed grade 3 neutropenia (15.6%) and 37 patients developed grade 4 neutropenia (57.8%). Conclusion: This study demonstrates a high incidence of FN post-TCH chemotherapy thus supporting the use of granulocyte colony-stimulating factor as primary prophylaxis.
dc.publisherFuture Medicine
dc.publisher.placeUnited Kingdom
dc.relation.ispartofjournalBreast Cancer Management
dc.subject.fieldofresearchCancer Cell Biology
dc.titleHigh Incidence of Febrile Neutropenia Following Adjuvant Breast Chemotherapy with Docetaxel, Carboplatin and Trastuzumab
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorSanmugarajah, Jasotha

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record